ADP-A2M4CD8

Overview

Overview

ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by leveraging CD4+ cells into CD8+ killer or cytotoxic T‑cells while retaining their CD4+ helper function.

Cancer indications in the SURPASS Trial

Ovarian

Ovarian

Ovarian cancer begins in the ovaries, which are made up of three main kinds of cells. Each type of cell can develop into a different type of tumor.

Head and Neck

Head and Neck

Head and neck cancers arise in the epithelium of the paranasal sinuses, nasopharynx, oropharynx, oral cavity, hypopharynx and larynx.

Bladder

Bladder

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is the most common type of bladder cancer.

Publications

Review our findings and publications.